NO951498L - Farmasöytisk preparat for behandling av osteoporose - Google Patents

Farmasöytisk preparat for behandling av osteoporose

Info

Publication number
NO951498L
NO951498L NO951498A NO951498A NO951498L NO 951498 L NO951498 L NO 951498L NO 951498 A NO951498 A NO 951498A NO 951498 A NO951498 A NO 951498A NO 951498 L NO951498 L NO 951498L
Authority
NO
Norway
Prior art keywords
osteoporosis
treatment
pharmaceutical preparation
xantohumol
therapeutic agent
Prior art date
Application number
NO951498A
Other languages
English (en)
Norwegian (no)
Other versions
NO951498D0 (no
Inventor
Hiroyasu Tobe
Kazuyuki Kitamura
Osamu Komiyama
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of NO951498D0 publication Critical patent/NO951498D0/no
Publication of NO951498L publication Critical patent/NO951498L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO951498A 1994-04-21 1995-04-20 Farmasöytisk preparat for behandling av osteoporose NO951498L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6082852A JPH07285856A (ja) 1994-04-21 1994-04-21 骨粗鬆症治療剤

Publications (2)

Publication Number Publication Date
NO951498D0 NO951498D0 (no) 1995-04-20
NO951498L true NO951498L (no) 1995-10-23

Family

ID=13785904

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951498A NO951498L (no) 1994-04-21 1995-04-20 Farmasöytisk preparat for behandling av osteoporose

Country Status (14)

Country Link
US (1) US5679716A (ko)
EP (1) EP0679393B1 (ko)
JP (1) JPH07285856A (ko)
KR (1) KR100350564B1 (ko)
AT (1) ATE162073T1 (ko)
AU (1) AU695696B2 (ko)
CA (1) CA2147419A1 (ko)
DE (1) DE69501419T2 (ko)
DK (1) DK0679393T3 (ko)
ES (1) ES2116642T3 (ko)
FI (1) FI951856A (ko)
HU (1) HUT71603A (ko)
NO (1) NO951498L (ko)
TW (1) TW284687B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008208A (en) * 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
DE19939350B4 (de) * 1999-08-19 2005-04-07 Plantextrakt Gmbh & Co. Kg Hopfenextrakt und Verfahren zu dessen Herstellung
KR20060095786A (ko) * 2000-01-27 2006-09-01 다카라 바이오 가부시키가이샤 치료제
US20040002423A1 (en) * 2000-04-10 2004-01-01 Hiromu Ohnogi Remedies
US6352726B1 (en) * 2001-01-09 2002-03-05 S. S. Steiner, Inc. Method of killing protozoa
BR0208418A (pt) * 2001-04-05 2004-03-30 Unilever Nv Uso de isoxantohumol e/ou xantohumol, método para administrar isoxantohumol e/ou xantohumol a seres humanos em necessidade de receber um componente ani-inflamatório ou anti-envelhecimento, e, produto alimentìcio
FR2823672B1 (fr) * 2001-04-23 2004-03-12 Berkem Sa Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes
KR100993113B1 (ko) * 2002-02-14 2010-11-08 기린 홀딩스 가부시키가이샤 지질대사 개선용 조성물 및 식품
AU2002257721A1 (en) * 2002-04-24 2003-11-10 Unilever Plc Use of hop components in foods
DE10240065B4 (de) * 2002-08-30 2004-10-28 Hallertauer Hopfenveredlungsgesellschaft M.B.H. Verfahren zur Gewinnung von in Hopfen enthaltenem Xanthohumol und damit erhältlicher Xanthohumol-reicher Hopfenextrakt
DK1431385T3 (da) * 2002-12-18 2006-07-31 Doehler Gmbh Xanthohumolholdig drik
ATE407667T1 (de) * 2003-04-08 2008-09-15 Kirin Brewery Zusammensetzung zur hemmung oder prävention der verringerung der knochendichte
DE102004063125B4 (de) 2004-12-22 2007-03-15 Ta-Xan-Ag Natürlicher Xanthohumol-haltiger Extrakt sowie das Verfahren zu dessen Herstellung und daraus hergestellte Getränke
CA2617209A1 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations
DE102006062264A1 (de) * 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
KR101323150B1 (ko) * 2011-04-25 2013-10-30 충남대학교산학협력단 잔토휴몰을 함유하는 골다공증 예방 및 치료용 조성물
CN103371989A (zh) * 2012-04-24 2013-10-30 华东师范大学 黄腐酚在制备抑制破骨细胞分化和蚀骨功能的预防和/或治疗药物中的应用
DK2877167T3 (da) * 2012-07-26 2020-10-12 Arcaini Antonio Anvendelse af sammensætninger indeholdende et ristet ekstrakt og xanthohumol
JP6009498B2 (ja) * 2014-06-24 2016-10-19 国立大学法人京都大学 アルツハイマー病予防薬
US20180193287A1 (en) 2015-07-02 2018-07-12 John I. Haas, Inc. Hops-based substance and use of the substance
CN105477686B (zh) * 2015-11-30 2019-02-15 长春工业大学 一种包覆黄腐酚的纳米纤维膜

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794744A (en) * 1972-05-10 1974-02-26 White Tomkins Ltd Purification of hop extracts
US4065574A (en) * 1975-08-29 1977-12-27 The Upjohn Company New method for controlling fungi using 4-chromone, 4-chromanone, 4-chromone oxime and 4-chromanone oxime compounds

Also Published As

Publication number Publication date
ES2116642T3 (es) 1998-07-16
TW284687B (ko) 1996-09-01
HU9501121D0 (en) 1995-06-28
FI951856A0 (fi) 1995-04-19
US5679716A (en) 1997-10-21
AU695696B2 (en) 1998-08-20
DE69501419D1 (de) 1998-02-19
AU1653595A (en) 1995-10-19
EP0679393A3 (en) 1995-11-15
DK0679393T3 (da) 1998-09-14
EP0679393B1 (en) 1998-01-14
ATE162073T1 (de) 1998-01-15
KR950031060A (ko) 1995-12-18
JPH07285856A (ja) 1995-10-31
KR100350564B1 (ko) 2002-12-16
NO951498D0 (no) 1995-04-20
EP0679393A2 (en) 1995-11-02
DE69501419T2 (de) 1998-06-25
HUT71603A (en) 1996-01-29
CA2147419A1 (en) 1995-10-22
FI951856A (fi) 1995-10-22

Similar Documents

Publication Publication Date Title
NO951498L (no) Farmasöytisk preparat for behandling av osteoporose
ATE200733T1 (de) Pharmazeutische zubereitungen, die fluoxetin enthalten
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
PT998287E (pt) Utilizacao de levobupivacaina
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
GR3025568T3 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia.
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
NO996438L (no) Ny kombinasjon av antiastmamedikamenter
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
NO952411L (no) Midler for behandling av metaboliske bensykdommer
MXPA05005460A (es) Contraste de ultrasonido que usa xantenos halogenados.
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
WO1998038986A3 (en) Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections
UA30143A (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
AR003117A1 (es) El uso de derivado de aminotetralina para la preparacion de composiciones farmaceuticas para la terapia de enfermedades cardiovasculares y dichascomposiciones farmaceuticas.
WO2001095916A3 (de) Anticholestatisches arzneimittel
NO890742L (no) Farmasoeytisk preparat som sikrer den transdermale absorpsjon av aktiv bestanddel, og fremgangsmaate for fremstillingav dette.
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.
HUP0004475A2 (hu) Gyógyszerkészítmény

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application